Armed with the genetic evidence of mutations involving KRAS and CDK6/CDK14 as well as the response to single agent therapies, we reasoned that treatment with a combination of drugs addressing the key mutations associated with propagation and metastasis in the CB42 should result in tumor regression. The gene discussed is KRAS; the disease is neoplasm.